Yan Liu, MD, PhD, RPVI, FACC

Director, Cardiology/Oncology Service

Director, Cardiovascular Research

Bayview Cardiovascular Associates/Sentara Heart Center

Assistant Professor of Medicine

East Virginia Medical School

Clinical Assistant Professor of Medicine

Division of Cardiology, School of Medicine

University of North Carolina at Chapel Hill

President, BLCMS Medical Society, Texas Medical

Association

yan.liu@bayviewphysicians.com

https://twitter.com/DrYanLiu

Dr. Liu obtained his medical degree in 1999 from a combined 7-year program of clinical medicine at Harbin Medical University in China. He later received his Ph.D. in Immunology at Duke University with the honor of the Bernard Amos Research Award. He was then selected as the NIH Joseph Pogano Research Fellow and established himself as a leader in the field of molecular aging, atherosclerosis and chemo-protection while working with Dr. Norman Sharpless, a renowned oncologist and current director of the National Cancer Institute. Dr. Liu’s work on aging biomarker and genetic susceptibility of CAD/atherosclerosis had been featured on BBC World News, SicenceDaily and etc. He resumed his clinical training at UT Southwestern and UNC-Chapel Hill for his residency and cardiology fellowship, respectively. He served as the Chief Cardiology Fellow at UNC-Chapel Hill before serving as the Clinical Assistant Professor of Medicine at UNC-CH。

As a staff cardiologist and a partner of Austin Heart/Hospital Corporation of America (HCA) Physician Group. He served as the Chair of Anticoagulation Committee and the director for the 12-location Anticoagulation Clinics, one of the largest Anticoagulation Clinics in US. He has served on the Expert Panel of Texas Medical Board, a public speaker of American Heart Association, and the President of the Burnet, Lampasas County Medical Society, a section of Texas Medical Association.

Dr. Liu was then appointed as the Director of Cardiology/Oncology Service and Cardiovascular Research at Bayview Cardiovascular Associates/Sentara Heart Center. Sentara Heart is ranked 24th in Cardiology/Cardiac Surgery by US News in 2018. It is the top ranked non-university based heart institution in US. He is also a partner of the Bayview Physician Group.

Dr. Liu’s clinical specialties are clinical cardiology, cardio-oncology. cardiac critical care,  cardiovascular and nuclear imaging. He is Board-Certified in Cardiovascular Medicine, Echocardiogram, Nuclear Cardiology, Vascular Interpretation (RPVI) and Internal Medicine. He is also a pioneer in ACC Cardio-oncology section. His current research interest lies in translational research/clinical trials involving novel biomarkers, molecular and deep learning models in cardiovascular disease prediction and cardiotoxicity protection. He has authored over 20 peer-reviewed original articles and multiple patents leading to two start-up biopharmaceutical companies and one Nasdaq-listed company. He has a total current SCI citation of over 1500.

Dr. Liu is a Fellow of American College of Cardiology (FACC), a member of American Association of Immunologist (AAI), a member of American College of Physicians, American Heart Association, American Society of Echocardiography, and American Society of Nuclear Cardiology. He is a member of American Physician Scientist Association (APSA), Texas Medical Association (TMA) and American Medical Association (AMA). He has been a reviewer for “Aging Cell” and “Aging and Disease”. He also serves as the current Director of Cardio-Oncology, and Director of Clinical Trial/Evidence-based Medicine at Chinese American Heart Association (CNAHA). He is an Archie Robinson Physician Award Winner of HCA, an American Medical Association (AMA) Seed Grant Winner. He serves as an Expert Panelist on Texas Medical Board and the President of BLCMS Medical Society of Texas Medical Association.

SELECTED PUBLICATIONS (out of 24 total):

SCI citation information on Google Scholar:

https://scholar.google.com/citations?user=bhQcuyMAAAAJ&hl=en

A full list of publication is also available on NCBI PubMed:

https://www.ncbi.nlm.nih.gov/myncbi/browse/collection/42276934/?sort=date&direction=ascending

1. Clark AL, Liu Y, Katz JN, Stouffer GA. Biventricular Stress-induced Cardiomyopathy and Cardiogenic Shock Secondary to Rheumatoid Arthritis Flare. J Clin Exp Cardiolog 2016; 7:461

2. Misenheimer JA, Liu Y, Means G, Kaul P, and Yeung M. Pneumopericardium Secondary to Gastro-Pericardial Fistula Presenting as Acute Pericarditis with Evidence of Cardiac Tamponade. J Am Coll Cardiol Intv. 2016;9(16):1748-1749.

3. Liu Y, Mingyu Zhang. IFNα21 Correlates with ARF and non-coding RNA ANRIL Expression and the Age of CAD Onset in Han Chinese. J Am Coll Cardiol. 2015;66(16_S)

4. Liu Y, Dai Xuming. Fellow-Initiated Clinical Trials: Opportunities, Challenges and Strategies. J Am Coll Cardiol, 2015;66(3):324-327

5. Nelson JE, Krishnamurthy J, Menezes P, Liu Y, Hudgens MG, Sharpless NE, Eron JJ. (2012) Expression of p16INK4a correlates with increasing age and decreased CD4 count in patients on effective ART. Aging Cell, 2012 Oct;11(5):916-8

6. Liu Y, Johnson SM, Fedoriw Y, Rogers A, Yu H, Krishnamurthy J and Sharpless NE. Expression of p16INK4a prevents cancer and promotes aging in lymphocytes. Blood. 2011 Mar 24;117(12):3257-67. Commentary: Eshraghi P, Rudolph KL. Lineage-specific pleiotropy in immune aging. Blood. 2011 Mar 24;117(12):3250-1.

7. Kuo CL, Murphy AJ, Sayers S, Li R, Yvan-Charvet L, Davis JZ, Krishnamurthy J, Liu Y, Puig O, Sharpless NE, Tall AR, Welch CL. Cdkn2a Is an Atherosclerosis Modifier Locus That Regulates Monocyte/Macrophage Proliferation. Arterioscler Thromb Vasc Biol. 2011 Nov;31(11):2483-2492.

8. Burd CE, Jeck WR, Liu Y, Sanoff HK, Wang Z, Sharpless NE. Expression of Linear and Novel Circular Forms of an INK4/ARF-Associated Non-Coding RNA Correlates with Atherosclerosis Risk. PloS Genet. 2010 Dec 2;6(12):e1001233

9. Liu Y and Sharpless NE. Tumor suppressor mechanisms in immune aging. Current Opinion in Immunology. 2009 Aug; 21(4): 431-439

10. Song Z, von Figura G, Liu Y, Kraus JM, Torrice C, Dillon P, Rudolph-Watabe M, Ju Z, Kestler HA, Sanoff H, Lenhard Rudolph K. Lifestyle impacts on the aging-associated expression of biomarkers of DNA damage and telomere dysfunction in human blood. Aging Cell. 2010 Aug;9(4):607-15

11. Liu Y., Sanoff, HK, Cho H, Burd CE, Torrice C, Ibrahim JG, Thomas NE, and Sharpless NE. (2009) Expression of p16INK4a in peripheral blood T-cells is a biomarker of human aging. Aging cell. 2009 Aug; 8(4): 439-448

12. Liu Y, Sanoff, HK, Cho H, Burd CE, Torrice C, Mohlke KL, Ibrahim JG, Thomas NE, and Sharpless NE. INK4/ARF transcript expression is associated with chromosome 9p21 variants linked to atherosclerosis. PLoS ONE. 2009 Apr; 4(4): 5027.

13. Tsygankov D, Liu Y, Sanoff HK, Sharpless NE, Timothy CE. A Quantitative Model for Age-Dependent Expression of the p16INK4a Tumor Suppressor. PNAS. 2009 Sep;106(39):16562-7.

14. Liu Y and Zhang W. Identification of a new transmembrane adaptor protein that constitutively binds Grb2 in B cells. J Leu Bio. 2008 Sep; 84(3):842-51.

15. Liu Y, Zhu M, Nishida K, Hirano T, Zhang W. An essential role for RasGRP1 in mast cell function and IgE-mediated allergic response. J Exp Med. 2007 Jan; 204(1):93-103.

16. Guo XC, Scott K, Liu Y, Dean M, David V, Nelson GW, Johnson RC, Dilks HH, Lautenberger J, Kessing B, Martenson J, Guan L, Sun S, Deng H, Zheng Y, de The G, Liao J, Zeng Y, O'Brien SJ, Winkler CA. Genetic factors leading to chronic Epstein-Barr virus infection and nasopharyngeal carcinoma in South East China: study design, methods and feasibility. Hum Genomics. 2006 Jun; 2(6):365-75

17. Zhu M, Koonpaew S, Liu Y, Shen S, Denning T, Dzhagalov I, Rhee I, Zhang W. Negative regulation of T cell activation and autoimmunity by the transmembrane adaptor protein LAB. Immunity. 2006 Nov; 25(5):757-68.

18. Zhu M, Rhee I, Liu Y, Zhang W. Negative regulation of FcåRI-mediated signaling and mast cell function by the adaptor protein LAX. J Biol Chem. 2006 Jul; 281(27):18408-13.

19. Zhu M, Shen S, Liu Y, Granillo O, Zhang W. Cutting Edge: Localization of linker for activation of T cells to lipid rafts is not essential in T cell activation and development. J Immunol. 2005 Jan; 174(1):31-55

20. Zhu M, Liu Y, Koonpaew S, Granillo O, Zhang W. Positive and negative regulation of FcåRI-mediated signaling by the adaptor protein LAB/NTAL. J Exp Med. 2004 Oct; 200:991-1000